Barinthus Bio promotes Geoffrey Lynn to CSO; Nadège Pelletier steps down

Barinthus Biotherapeutics plc.

Nadège Pelletier to step down as Chief Scientific Officer effective Feb 2, 2025; she served since early 2023.
Geoffrey Lynn, M.D., Ph.D. promoted to CSO effective Dec 1, 2024; he is co-inventor of SNAP-TI technology.
Lynn previously led Avidea Technologies (acquired by Barinthus in 2021) and holds M.D. from Johns Hopkins, D.Phil. from Oxford.
Company highlights pipeline progress: VTP-300 in chronic hepatitis B, VTP-1000 (SNAP-TI) in Phase 1 for celiac disease.
Transition expected to be smooth; Pelletier will remain until responsibilities transitioned.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nadège Pelletier

Chief Scientific Officer

BRNS · Barinthus Biotherapeutics plc.

Effective: 2025-02-02
Filed: November 25, 2024, 6:59 PM ET

On November 25, 2024, Nadège Pelletier, Ph.D., notified Barinthus Biotherapeutics plc (the "Company") that she will step down as Chief Scientific Officer of the Company effective February 2, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nadège Pelletier departed as Chief Scientific Officer at Barinthus Biotherapeutics plc..

Action: step down
Role: Chief Scientific Officer

Exact text from the filing

On November 25, 2024, Nadège Pelletier, Ph.D., notified Barinthus Biotherapeutics plc (the "Company") that she will step down as Chief Scientific Officer of the Company effective February 2, 2025.

View on SEC.gov

Barinthus Biotherapeutics plc. filing history →

Source: SEC EDGAR

accession 0001828185-24-000093

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.